Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/1697
Title: Evaluation of ticarcillin/clavulanic acid versus ceftriaxone plus amikacin for fever and neutropenia in pediatric patients with leukemia and lymphoma
Authors: Petrilli, Antonio Sergio [UNIFESP]
Cypriano, Monica [UNIFESP]
Dantas, Lenice Silva [UNIFESP]
Lee, Lúcia Martino [UNIFESP]
Luisi, Maria Flávio Augusto Vercillo [UNIFESP]
Silva, Katia Veronica Torres B. [UNIFESP]
Pereira, Carlos Alberto Pires [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Keywords: Fever
neutropenia
leukemia
lymphoma
ticarcillin
ceftriaxone
Issue Date: 1-Apr-2003
Publisher: Brazilian Society of Infectious Diseases
Citation: Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 7, n. 2, p. 111-120, 2003.
Abstract: BACKGROUND: The empirical use of antibiotic treatments is widely accepted as a means to treat cancer patients in chemotherapy who have fever and neutropenia. Intravenous monotherapy, with broad spectrum antibiotics, of patients with a high risk of complications is a possible alternative. METHODS: We conducted a prospective open-label, randomized study of patients with lymphoma or leukemia who had fever and neutropenia during chemotherapy. Patients received either monotherapy with ticarcillin/clavulanic acid (T) or ceftriaxone plus amikacin (C+A). RESULTS: Seventy patients who presented 136 episodes were evaluated, 68 in each arm of the study. The mean neutrophil counts at admission were 217cells/mm³ (T) and 201cells/mm³ (C+A). The mean duration of neutropenia was 8.7 days (T) and 7.6 days (C+A). Treatment was successful without the need for modifications in 71% of the episodes in the T group and 81% in the C+A group (p=0.23). Treatment was considered to have failed because of death in two episodes (3%) in the T group and three episodes (4%) in the C+A group, and because of a change in the drug applied in one episode in the T group and two episodes in the C+A group. Overall success was 96% (T) and 93% (C+A). Adverse events that occurred in group T were not related to the drugs used in this study. CONCLUSION: In pediatric and adolescent patients with leukemia or lymphoma, who presented with fever and neutropenia, during chemotherapy, ticarcillin/clavulanic acid was as successful as the combination of ceftriaxone plus amikacin. It should be considered an appropriate option for this group of patients at high risk for infections.
URI: http://repositorio.unifesp.br/handle/11600/1697
ISSN: 1413-8670
Other Identifiers: http://dx.doi.org/10.1590/S1413-86702003000200003
Appears in Collections:Artigo

Files in This Item:
File Description SizeFormat 
S1413-86702003000200003.pdf35.77 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.